文献速递妇科

依据VALHUDES方案比较EUROArray HPV检测在自采样与医生采样样本中对宫颈癌前病变的准确性

EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol.
PubMed 文献 · Gynecol Oncol · 2025-09-10

VALHUDES框架下五家阴道镜诊所纳入宫颈结果异常患者,比较阴道自采样和首段尿自采样与医生采集宫颈样本的EUROArray HPV检测准确性。阴道自采样和首段尿的CIN2+相对敏感度均为0.96,相对特异度分别为0.98和0.94。结论认为EUROArray HPV在自采样与医生采样样本上的准确性相似。

要点

  • 阴道自采样CIN2+相对敏感度0.96(95%CI 0.91-1.02),首段尿0.96(95%CI 0.90-1.05)。
  • 阴道自采样相对特异度0.98(95%CI 0.91-1.07),首段尿0.94(95%CI 0.85-1.04)。
  • EUROArray HPV在阴道自采样和首段尿与医生采样宫颈样本上准确性相似。

核心结论

  • EUROArray HPV在阴道自采样和首段尿样本上的准确性与医生采集的宫颈样本相似。

研究设计与样本

  • VALHUDES框架设计用于评估自采样HPV检测准确性,五家阴道镜诊所纳入宫颈结果异常患者。
  • 患者采集首段尿(Colli-Pee)和阴道自采样(Evalyn Brush或Qvintip),并采集医生宫颈样本作为对照。
  • 所有样本取0.4 mL用于Abbott m2000 DNA提取,50 μL洗脱,取5 μL DNA提取物用EUROArray HPV检测高危HPV。
  • 疾病结局由阴道镜伴或不伴活检确定,比较各型自采样与医生采样的相对准确性。

主要发现

  • 阴道自采样和首段尿分别有491和494对匹配样本数据可用。
  • 阴道自采样CIN2+相对敏感度0.96(95%CI 0.91-1.02),首段尿CIN2+相对敏感度0.96(95%CI 0.90-1.05)。
  • 阴道自采样<CIN2相对特异度0.98(95%CI 0.91-1.07),首段尿<CIN2相对特异度0.94(95%CI 0.85-1.04),自采样相对特异度未显著低于医生采样。

临床怎么用

  • 原文未据此给出临床推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Human papillomavirus (HPV) testing on self-collected urine and vaginal samples has shown great potential for cervical cancer screening by offering a non-invasive and approachable alternative to un(der)screened populations. Although many HPV tests were validated on cervical samples, data regarding clinical performance on self-samples is warranted prior to its clinical use. METHODS: The VALHUDES framework was designed to evaluate the accuracy of HPV tests on self-samples. As such, five colposcopy clinics enrolled patients with aberrant cervical results, asking them to collect a first-void urine (Colli-Pee) and a vaginal self-sample (Evalyn Brush or Qvintip). Additionally, a clinician-collected cervical sample was collected as comparator. 0.4 mL of all samples was used for DNA extraction with Abbott m2000, eluting in 50 μL. To detect high-risk HPV, PCR was conducted on 5 μL DNA extract from all samples with the EUROArray HPV test. Disease outcome was determined by colposcopy with or without biopsy. Relative accuracy was estimated for each self-sample type compared to the clinician-collected sample. RESULTS: Data was available from 491 and 494 matched samples for vaginal and first-void urine self-samples, respectively. Relative sensitivity for CIN2+ was 0.96 (95 % CI: 0.91-1.02) for vaginal self-samples and 0.96 (95 % CI: 0.90-1.05) for first-void urine. The specificity for <CIN2 was also not significantly lower on the self-samples compared to clinician-taken samples (relative specificity: 0.98 [95 % CI: 0.91-1.07] for vaginal self-samples and 0.94 [95 % CI: 0.85-1.04] for first-void urine). CONCLUSIONS: The accuracy of EUROArray HPV is similar on vaginal self-samples and first-void urine compared to clinician-collected cervical samples.

来源:Gynecol Oncol,查看原文。版权归原作者所有。

引用

  1. van den Borst E, Vanden Broeck D, De Sutter P, et al. EUROArray HPV test accuracy for cervical precancer in self- vs. clinician-collected samples using the VALHUDES protocol. Gynecol Oncol. 2025. PMID: 40934859. doi:10.1016/j.ygyno.2025.08.018

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。